Cabaletta Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-06-01
- Employees
- 103
- Market Cap
- $281.3M
- Website
- http://www.cabalettabio.com
- Introduction
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Systemic Sclerosis Market to Exhibit Significant Growth by 2034
The systemic sclerosis market is projected to grow significantly by 2034, driven by increasing prevalence, patient awareness, and novel therapies. Key companies like Kyowa Hakko Kirin and AstraZeneca are developing treatments such as Brodalumab and CABA-201, which have received regulatory designations. The market dynamics are influenced by emerging therapies, diagnostic improvements, and challenges like treatment eligibility and reimbursement.
Cabaletta Bio Announces FDA Granted Orphan Drug Designation for CABA-201 in Treating Idiopathic Inflammatory Myopathies
Cabaletta Bio's CABA-201, a CD19-CAR T cell therapy, received FDA Orphan Drug Designation for treating idiopathic inflammatory myopathies (myositis). Targeting B cell-driven autoimmune diseases, CABA-201 aims to reset the immune system for durable remission. Four Phase 1/2 trials, including RESET-Myositis™, are evaluating its efficacy across autoimmune conditions.
© Copyright 2025. All Rights Reserved by MedPath